The US FDA should clarify the level of rigor needed for collecting patient experience data based upon how that information will be used in a drug’s development, industry and advocacy groups tell the agency.
In comments on a June draft guidance on collecting comprehensive and representative input, stakeholders pressed FDA to better define the different types of regulatory decisions that could be supported by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?